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Abstract
The purpose of this work was to determine SEPT9_v1 expression levels in head and neck squamous cell carcinoma
(HNSCC) and to analyze whether SEPT9_v1 expression is relevant to clinical outcomes. Recently, the SEPT9 isoform
SEPT9_v1 has been implicated in oncogenesis, and methylation of the SEPT9 promoter region was reported in
HNSCC. These findings led us to hypothesize that SEPT9_v1 could be differently expressed in HNSCC. To determine
whether SEPT9_v1 is expressed in HNSCC, tissuemicroarray immunohistochemical analysis was performed using a
SEPT9_v1-specific antibody. Tissue microarrays stained with a polyclonal SEPT9_v1-specific antibody was used to
determine protein expression levels in HNSCC tissue samples, some with known clinical outcomes. This analysis
showed that SEPT9_v1 is in fact highly expressed in HNSCC compared with normal epithelium, and high expression
levels directly correlated with poor clinical outcomes. Specifically, a high SEPT9_v1 expression was associated with
decreased disease-specific survival (P = .012), time to indication of surgery at primary site (P = .008), response to
induction chemotherapy (P = .0002), and response to chemotherapy (P = .02), as well as advanced tumor stage
(P = .012) and N stage (P = .0014). The expression of SEPT9_v1 was also strongly correlated with smoking status
(P = .00094). SEPT9_v1 is highly expressed in HNSCC, and a high expression of SEPT9_v1 is associated with poor
clinical outcomes. These data indicate that SEPT9_v1 warrants additional investigation as a potential biomarker
for HNSCC.
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Introduction
Head and neck cancers are a complex heterogeneous set of solid tumor
malignancies marked by diverse molecular mechanisms. Alterations in
p53 [1–5], loss of p16 [3,6–9], amplification of cyclin D1 [3,4,6,10],
and overexpression of epidermal growth factor receptor [3,11–13] are
all important mechanisms in the progression of head and neck cancers.
Recently, methylation of the SEPT9 promoter was identified in a
genome-wide screen of head and neck cancers [14]. Methylation of
the promoter region of a gene generally results in silencing of the locus.
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This is achieved by condensing the chromatin which limits the tran-
scription machinery’s access to the locus. Although this study found
that SEPT9 expression was decreased in a subset of head and neck squa-
mous cell carcinoma (HNSCC) samples studied, it did not look at each
individual SEPT9 variant encoded at the locus to determine which spe-
cific variants were silenced. Because high SEPT9_v1 expression has
been implicated in breast, ovarian, and prostate cancers [15–17], we
were interested in determining whether SEPT9_v1 expression plays a
role in HNSCC, hypothesizing that this unique variant may be upreg-
ulated whereas other variants are silenced as previously suggested in
breast cancer [17].
SEPT9 belongs to a highly conserved family of proteins called
Septins originally described in Saccharomyces cerevisiae. This family
of proteins has proven to be important for faithful cell cycle progres-
sion and bud morphology. Mutation analysis of SEPT9 found that it
functions in cell division and cell cycle progression through its inhi-
bition of cyclin-dependent kinases necessary for progression through
G2-M [18]. Because of its role in cell division and cell cycle progres-
sion, SEPT9 has been implicated in oncogenesis. SEPT9 has been
shown to go through alternative splicing at both ends, resulting in a
variety of transcripts, which are found to be differentially expressed.
In addition, SEPT9 variants possess unique promoter sequences, al-
lowing for distinct regulation of each variant. It seems as though altered
expression of these variants is responsible for the development of ma-
lignancies because no specific mutations in either the introns or the
exons of SEPT9 have been found [19].
One SEPT9 variant, SEPT9_v1, has been shown to be highly ex-
pressed in breast, ovarian, and prostate cancers [15–17]. In prostate
cancer models, SEPT9_v1 interacts with hypoxia-inducible factor 1α,
which increases angiogenesis [15]. In immortalized human mammary
epithelial cells (IHMECs), overexpression of SEPT9_v1 results in on-
cogenic phenotypes including an epithelial-to-mesenchymal transition,
increased cellular proliferation, invasiveness, aneuploidy, disrupted tu-
bulin filaments, promoted binucleated cells, and abnormal localization
of SEPT9_v1 to the nucleus [17]. In addition, SEPT9_v1 acts to sta-
bilize c-Jun N-terminal kinase (JNK) and prevents its degradation [20].
The JNK signaling pathway is known to play a role in cell proliferation
and tumorigenesis. Interestingly, JNK expression and subsequent ki-
nase activity are increased in HNSCC [21].
Head and neck cancers are a heterogeneous group of cancers, which
are marked by their aggressiveness and invasiveness. HNSCCs are
associated with poor prognosis and clinical outcome owing to this fea-
ture, making the identification of prognostic marker(s) all the more
important. On the basis of the data described here, SEPT9_v1 has
the potential to emerge as an important prognostic and therapeutic
biomarker for HNSCC.
Materials and Methods
Tissue Microarray Construction
Tissue microarray (TMA) 74 was constructed using HNSCC sam-
ples from 11 patients. These 11 patients provided multiple tumor sam-
ples. In five patients, normal samples were also present and analyzed as a
matched set.
TMA 96was constructed as previously described [3]. Briefly, samples
were obtained from a clinical trial of 50 patients with either stage III or
IV squamous cell carcinoma of the oropharynx. All samples were ob-
tained pretreatment, and patients were subsequently followed through
treatment protocols.
Figure 1. Composite showing representative staining in TMA 74. Panel #1 shows normal epithelium as indicated by the arrows and no
SEPT9_v1 staining. Panel #2 shows low SEPT9_v1 staining. Panel #3 shows medium SEPT9_v1 staining. Panel #4 shows high SEPT9_v1
staining and perineural invasion, indicated by the arrowheads.
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Immunohistochemistry
A custom rabbit polyclonal SEPT9_v1-specific antibody was raised
to 17 of the unique 25 amino acids at the N-terminus of SEPT9_v1
(KKSYSGGTRTSSGRLRR) (BioCarta, San Diego, CA) [17]. Speci-
ficity of this antibody was demonstrated in previous studies [17,20].
Immunohistochemistry was performed at the University of Michigan
Histology and Immunohistochemistry Services Core Laboratory. Briefly,
antigen retrieval was performed using citrate, pH 6.0, and then micro-
waving for 10 minutes. Subsequent staining was performed on an auto-
stainer (DAKO,Carpinteria, CA) at room temperature. Primary SEPT9_v1
or immunoglobulin class G control antibody was used at a dilution of
1:200 and incubated for 30 minutes. Antirabbit EnVision+ was used to
detect the primary antibody. After this, the slide was incubated with
DAB and counterstained with hematoxylin.
TMA Scoring
Slides were reviewed for SEPT9_v1 staining by two investigators
who were blinded to clinical data (E.M. Petty and L. Stanbery). Slides
were scored by a head and neck pathologist (N.J. D’Silva) who was
blinded to clinical outcomes of the patients. Two criteria were used
to score the slides: intensity of antibody staining and percentage of
staining in the entire sample. Intensity of staining was scored on a scale
of 1 to 4: 1, no or undetectable staining; 2, low staining; 3, medium
staining; and 4 high staining. Samples that had insufficient tissue pres-
ent were not scored or used for data analysis.
Statistics
TMA 74. Unpaired and paired t tests were used to determine
P value, with P ≤ .05 being statistically relevant.
TMA 96. Per protocol, patients received one cycle of induction
chemotherapy. Response to induction chemotherapy was recorded as
complete response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD). Subjects who responded to induction
chemotherapy (CR and PR) were treated with chemoradiation. Re-
sponse to chemoradiation therapy was recorded as complete response
and otherwise. Subjects who were SD and PD to induction chemo-
therapy or those who did not respond to chemoradiation received sur-
gery with therapeutic intend. The outcomes of interest, other than
Figure 2. Probability of survival over time according to SEPT9_v1 expression. Subjects were censored (black vertical bar) when they did
not experience an event.
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response to induction chemotherapy and response to chemoradiation
therapy, were overall survival, disease-specific survival, time to indica-
tion of surgery at primary site, and time to recurrence or second pri-
mary. For time to indication of surgery at primary site, the events were
SD or PD after induction chemotherapy that required surgery at the
primary site, local recurrence after chemoradiation therapy that re-
quired surgery at the primary site, and never disease-free. For the
outcome of time to recurrence or second primary, the events included
recurrences, relevant second primaries, and never disease-free. The
covariates of interest were T stage and N stage, which were analyzed
as ordinal data.
The Spearman correlation coefficient was used to evaluate asso-
ciations between marker levels and ordinal variables of interest, such
as induction chemoresponse and chemoradiation response T and
N stage. The Cox proportional hazards model was used to relate
time-to-event outcomes to marker levels and demographic and clini-
cal variables.
All statistical analyses were done using Statistical Analysis System
version 9.0 (SAS, Cary, NC). Two-tailed P ≤ .05 was considered to
be statistically significant.
Results and Discussion
High expression of SEPT9_v1 has been associated with the patho-
genesis of several cancers and acquisition of oncogenic phenotypes
in IHMECs [17]. We wanted to analyze the role of SEPT9_v1 expres-
sion in HNSCC. To this end, we used a tissue microarray constructed
from patient samples and stained using a SEPT9_v1-specific anti-
body. Each sample was then scored by a pathologist for expres-
sion level of SEPT9_v1 (Figure 1) as well as percent staining of the
total sample.
TMA 74 (Figure 1) was used to determine whether there was any
correlation between SEPT9_v1 expression and normal versus tumor
tissue. We determined that SEPT9_v1 was expressed highly in tumor
samples versus normal samples (P = .0033). In addition, when compar-
ing matched samples from the five patients studied, we saw a strong
correlation between high SEPT9_v1 expression and tumor samples
(P = .0064). This indicates that SEPT9_v1 was not originally highly
expressed in the normal tissues of these patients.
Using TMA 96, we found that high expression of SEPT9_v1 was
associated with several less favorable outcomes, including decreased
disease-specific survival (P = .012; Figure 2) and time to indication
Figure 3. Probability of a patient needing surgery at the primary site over time. Subjects were censored (black vertical bar) when they did
not experience an event, that is, death from an unrelated event.
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of surgery at primary site (P = .008; Figure 3). Patients with tumors
with no SEPT9_v1 had virtually no need for surgery at the primary
site. The indication for surgery increased, with increasing levels of
SEPT9_v1 being present. SEPT9_v1 expression also correlated with
the probability of disease-specific survival. Patients with no SEPT9_v1
expression had a significantly higher survival rate, whereas increasing
Figure 4. (a) Patient response to induction chemotherapy as a
function of mean SEPT9_v1 intensity. Subjects were censored
when no event was experienced. Horizontal bar, median; box,
range. (b) Response to chemotherapy on the basis of SEPT9_v1
expression. Patients were classified into two groups: whether
they responded to chemotherapy or all others. Horizontal bar,
median; box, range; hollow circle, outlier.
Figure 5. T stage correlation with SEPT9_v1 intensity. Patients
were grouped on the basis of tumor size. Horizontal bar, median;
box, range; hollow circle, outliers.
Figure 6. N stage correlation with SEPT9_v1 intensity. Patients
were grouped on the basis of metastasis into the surrounding
lymph nodes. Horizontal bar, median; box, range; hollow circle,
outliers.
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levels of SEPT9_v1 resulted in decreased survival. These results indicate
that high levels of SEPT9_v1 are associated with less favorable outcomes.
Patients with tumors with high SEPT9_v1 expression showed poor
response to induction chemotherapy (P = .0002; Figure 4a) and had a
higher rate of progressive disease, whereas patients with a low SEPT9_v1
expression exhibited SD. Also, patients having tumors with low
SEPT9_v1 expression respond better to chemotherapy than patients
with tumors having high SEPT9_v1 expression (P = .02; Figure 4b).
The poor response to treatments seen in patients with high SEPT9_v1
may be the cause of the poor outcomes seen in these patients.
In addition, patients with stage IV cancer have higher expression of
SEPT9_v1 (P = .012; Figure 5). Stage IV cancers have usually
metastasized and are routinely associated with poor outcomes. In
addition to high SEPT9_v1 expression being correlated to T stage,
correlation with N stage status is also highly significant (P = .0014; Fig-
ure 6). This means that invasion into the surrounding lymph nodes
correlates with high SEPT9_v1 expression. Interestingly, metastatic
cells must gain the ability to be motile and to invade, two characteristics
that are seen in IHMECs expressing SEPT9_v1. In addition, advanced
Tand N stage could also be a result of poor response to induction che-
motherapy and chemotherapy, thus allowing the tumors to become
more advanced.
High SEPT9_v1 expression was also correlated with smoking status
(P = .0009) (Figure 7). Current smokers had high SEPT9_v1 expres-
sion. Interestingly, Bennett et al. [23] also found that SEPT9 promoter
methylation correlated with smoking status. We saw no correlation
with SEPT9_v1 expression and age or gender.
Although recent findings from Bennett et al. [14] showed that the
SEPT9 promoter in HNSCC is methylated and protein expression is
decreased, their study did not look at individual SEPT9 transcripts.
Their subsequent study also showed a correlation between promoter
methylation and smoking status [23]. There is evidence that each
transcript possesses its own promoter; therefore, methylation of one
promoter may only silence one transcript, whereas up-regulation of
another may occur. We have also seen different SEPT9 isoforms act-
ing differently in breast cancer [17]. For example, SEPT9_v1 and
SEPT9_v3, which differ in only the first 25 amino acids, have vastly
different phenotypes when expressed. Whereas SEPT9_v1 has a
tumorigenic effect, SEPT9_v3 has a tumor-suppressive–like effect
[18]. SEPT9 also forms homogenous and heterogenous complexes
with other septins to form filaments [19,24]. One hypothesis is a feed-
back loop, where low levels of one variant triggers another variant to
be expressed.
Conclusions
Collectively, these data suggest that a high expression of SEPT9_v1 is
associated with poor clinical outcomes in HNSCC. Furthermore, we
found that a high expression of SEPT9_v1 correlated with both ad-
vanced T and N stage, indicating that SEPT9_v1 may play a role in
motility and invasion. This hypothesis is supported by studies of
SEPT9_v1 expression in mammalian epithelial cells where increased
expression of SEPT9_v1 led to increased motility and invasion. Fur-
ther research needs to be conducted to determine the cause of high
SEPT9_v1 expression in HNSCC, and what role SEPT9_v1 is playing
in oncogenesis.
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